Background {#Sec1}
==========

Hirschsprung disease (HSCR) is a multifactorial disease characterized by the absence of ganglion cells in the bowel, causing a functional ileus in infants. It is divided into short-aganglionosis, long-aganglionosis, and total colon aganglionosis \[[@CR1], [@CR2]\]. Its frequency in Indonesia is higher (3.1:10,000) \[[@CR3]\] than other populations \[[@CR1], [@CR2]\]. This difference might be associated with the higher risk allele frequency of *RET* rs2435357 and rs2506030 in Indonesia compared with other populations \[[@CR4], [@CR5]\].

Ubiquitin N-recognin domain-containing E3 ligase 4 (UBR4) is a ubiquitin ligase protein that interacts with Ca^2+^ bound calmodulin in cytoplasm and might act as a regulator of Ca^2+^, that is released through ITPR1 \[[@CR6]\]. Bowel motility is determined by the synchronized activity of enteric nervous system (ENS), extrinsic nerves, immune cells, interstitial cells of Cajal (ICCs), and smooth muscle cells (SMCs) \[[@CR7]\]. ICCs are essential to generate and propagate the electrical cyclical activity (slow waves) in the intestines. The slow waves are transferred into the SMCs to make it depolarize cyclically, resulting in activation of calcium entry and intestines' contraction \[[@CR7]\]. In addition, previous study showed that *UBR4* is one of the novel HSCR genes with an excess of pathogenic alleles in HSCR patients and is expressed in the developing human and mouse fetal gut \[[@CR8]\]. Also, there is significant loss of enteric neuronal precursors after *ubr4*-knockdown in zebrafish embryos \[[@CR8]\]. Therefore, we determined the *UBR4* expressions in Indonesian HSCR patients with the hypothesis of the *UBR4* expressions decrease in the colon of patients with HSCR.

Material and methods {#Sec2}
====================

Patients {#Sec3}
--------

We involved HSCR patients who underwent pull-through from December 2014 until May 2019 at Dr. Sardjito Hospital, Indonesia \[[@CR9]\]. Their parents gave a signed informed consent before joining the study.

We obtained the ganglionic and aganglionic colon of HSCR patients during a pull-through and control colons during a stoma closure from anorectal malformation patients \[[@CR9]\].

The Institutional Review Board (IRB) of the Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital, approved the study (KE/FK/1105/EC/2018).

Real-time polymerase chain reaction (qPCR) {#Sec4}
------------------------------------------

Total RNA was obtained from HSCR patients and control colons according to our previous study \[[@CR9]\], followed by a qPCR to determine the *UBR4* expression using the following primer sets: 5′- TGGACACTCAGCTCACCAAG-3′ (forward) and 5′-GTTCCATCTTGACGCTCCTC-3′ (reverse) \[[@CR10]\]. *Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)* was employed as a reference gene for analysis of *UBR4* expression. We used the Livak method to compare the *UBR4* expressions between HSCR patients and control colons \[[@CR9], [@CR11]\].

Statistics {#Sec5}
----------

Data was provided as mean ± standard deviation (SD), median (interquartile range, IQR), or frequency. We utilized t-test to determine the significant differences of *UBR4* expression between the ganglionic, aganglionic, and control colon group. We determined a significant level by *p*-value of \< 0.05.

Results {#Sec6}
=======

Baseline characteristics {#Sec7}
------------------------

We involved 37 non-syndromic sporadic HSCR patients and 18 controls. Our patients revealed short-aganglionosis (70%) and long-aganglionosis (30%). Almost half of patients (46%) had transanal endorectal pull-through (46%). The median age at HSCR diagnosis was 4 (IQR, 1--34) months (Table [1](#Tab1){ref-type="table"}). Table 1Baseline characteristics of HSCR patients in Dr. Sardjito Hospital, IndonesiaCharacteristicsN (%); median (IQR)Gender ▪ Male26 (70.3) ▪ Female11 (29.7)Type of aganglionosis ▪ Short-segment29 (78.4) ▪ Long-segment8 (21.6) ▪ Total colon aganglionosis0Age at HSCR diagnosis (months)4 (1--34)Age at definitive surgery (months)6 (2--30)Definitive surgery ▪ Transanal endorectal pull-through17 (46) ▪ Transabdominal Soave13 (35) ▪ Duhamel7 (19)*HSCR* Hirschsprung disease, *IQR* interquartile range

UBR4 expressions in HSCR patients {#Sec8}
---------------------------------

qPCR revealed that the expression of *UBR4* was strongly decreased (0.77-fold) in the ganglionic compared to the control group (**ΔC**~**T**~ 2.43 ± 0.36 vs. 2.05 ± 0.69; *p* = 0.009), whereas the *UBR4* expression was also significantly reduced (0.79-fold) in the aganglionic compared to the control group (**ΔC**~**T**~ 2.39 ± 0.46 vs. 2.05 ± 0.69; *p* = 0.044) (Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). Table 2The *UBR4* expressions in the HSCR patients and control colons*UBR4* (ΔC~T~ ± SD)ΔΔC~T~ (95% CI)Fold change (2^-ΔΔC^~T~)*p*-valueGanglionic colon2.43 ± 0.360.39 (0.10--0.67)0.770.009\*Aganglionic colon2.39 ± 0.460.34 (0.01--0.67)0.790.044\*Control colon2.05 ± 0.69\*, *p* \< 0.05 is considered statistically significant; HSCR, Hirschsprung disease Fig. 1The *UBR4* expression was significantly down-regulated (0.77-fold) in the ganglionic colon group compared to the control group (*p* = 0.009), whereas the *UBR4* expression was also significantly decreased (0.79-fold) in the aganglionic colon group compared to the control group (*p* = 0.044). \*, *p* \< 0.05 is considered statistically significant

Next, we compared the *UBR4* expressions between ganglionic and aganglionic colon group. qPCR showed that the *UBR4* expressions were not significantly different between two groups (**ΔC**~**T**~ 2.43 ± 0.36 vs. 2.39 ± 0.46; *p* = 0.64).

Association between UBR4 expressions and baseline characteristic of HSCR patients {#Sec9}
---------------------------------------------------------------------------------

We examined the association between *UBR4* expressions with gender and degree of aganglionosis in HSCR patients in this cohort. The *UBR4* expressions were not significantly associated with gender (*p* = 0.35 and 0.80), nor with type of aganglionosis both in ganglionic and aganglionic colons (*p* = 0.72 and 0.73), respectively (Table [3](#Tab3){ref-type="table"}). Table 3Association between *UBR4* expressions and baseline characteristics of HSCR patients*UBR4*Male (*n* = 26) (ΔC~T~ ± SD)Female (*n* = 11) (ΔC~T~ ± SD)ΔΔC~T~ (95% CI)Fold change (2^-ΔΔC^~T~)*p*-valueGanglionic Colon2.40 ± 0.372.52 ± 0.35−0.12 (−0.38--0.14)1.090.35Aganglionic Colon2.38 ± 0.482.42 ± 0.45−0.05 (− 0.41--0.32)1.030.80Short-segment (*n* = 29) (ΔC~T~ ± SD)Long-segment (*n* = 8) (ΔC~T~ ± SD)Ganglionic Colon2.42 ± 0.382.48 ± 0.30− 0.05 (− 0.35--0.24)1.040.72Aganglionic Colon2.40 ± 0.462.32 ± 0.550.08 (− 0.39--0.55)0.950.73

Discussion {#Sec10}
==========

We are able to show for the first time the aberrant *UBR4* expression in HSCR patients. We determined *UBR4* expressions in the aganglionic, ganglionic, and control colons using qPCR. Our study reveals a significant difference of *UBR4* expression between HSCR patients' colons and control colons, implying that the aberrant *UBR4* expression could be one of the contributing factors of Indonesian HSCR patients.

UBR4 has a role in Ca^2+^ signaling and is involved in neuronal excitability \[[@CR12]\] since it interacts with Ca^2+^ bound calmodulin in cytoplasm and acts as a regulator of Ca2+, which is released through ITPR1 \[[@CR6]\]. Ca^2+^ signaling is important to maintain the intestines' motility, together with the synchronized activity of ENS, extrinsic nerves, immune cells, ICCs, and SMCs \[[@CR7]\]. The intestines' contraction is induced by the activation of calcium entry due to cyclically depolarization of SMCs. ICCs generate and propagate the slow waves to be transferred into SMCs \[[@CR7]\]. HSCR pathogenesis includes the compromised condition of genes responsible for the ENS development \[[@CR1], [@CR2], [@CR4], [@CR5], [@CR8]\], the neurotransmitters expressed by the ENS neurons \[[@CR13]\] and/or their interactions. Recently, pathogenic alleles within the *UBR4* gene have been shown to be associated with HSCR \[[@CR8]\]. Furthermore, a recent study demonstrated that the death of *Ubr4*-deficient mice embryos was correlated with developmental defects in various processes, including neurogenesis, due to failure to preserve cell integrity and adhesion \[[@CR14]\]. It has been shown that neurogenesis in embryos is strongly affected by the dysregulation of cell adhesion molecules \[[@CR15]\]. Lack of *UBR4* causes the rapid depletion of other cells' surface proteins as well, such as platelet-derived growth factor receptor (PDGFR) \[[@CR14]\]. In addition, previous study revealed that *SK3* is highly expressed in the PDGFRα+ cells \[[@CR13]\], which together with ICCs and SMCs regulate intestinal peristalsis \[[@CR16]\]. Our results further support the importance of *UBR4* in the HSCR pathogenesis by providing new evidence of the aberrant *UBR4* expressions in HSCR patients' colons. We hypothesize that the aberrant *UBR4* expressions contribute to the pathogenesis of HSCR in our patients by affecting the expression of *SK3* in the PDGFRα+ cells.

Moreover, our study for the first time demonstrated that the decreased *UBR4* expression also occurred in the ganglionic colon of HSCR patients. It has been shown that several aberrant gene expressions, including *SK3* \[[@CR9], [@CR17]\], *Cx26* and *Cx43* \[[@CR18]\], and *NOS* \[[@CR19]\], were significantly associated with the persistent intestinal symptoms in HSCR patients after an appropriately completed surgery. Whether the aberrant *UBR4* expression in the ganglionic colon is also correlated with the persistence of bowel symptoms after pull-through in HSCR patients warrants further investigation.

It should be noted that our study used ARM patient colon as control. To the best of our knowledge, there is no study comparing the *UBR4* expression between ARM patient colon and other colonic specimens. These facts should be considered during the interpretation of our findings since most ARM patients also show the intestinal motility problem \[[@CR20]\]. Therefore, further analysis using controls without any bowel motility problem is needed to confirm our results.

Moreover, future studies are necessary to further confirm the role of *UBR4* in the pathogenesis of HSCR by checking the decreased of UBR4 protein expressions using western blot or immunohistochemistry and screening the pathogenic variant in the *UBR4* gene using sequencing in HSCR patients.

Conclusion {#Sec11}
==========

Our study demonstrates that expression of *UBR4* is decreased in both aganglionic and ganglionic colon of HSCR patients.

ENS

:   Enteric nervous system

GAPDH

:   Glyceraldehyde-3-phosphate dehydrogenase

HSCR

:   Hirschsprung disease

ICCs

:   Interstitial cells of Cajal

qPCR

:   Quantitative real-time polymerase chain reaction

SMCs

:   Smooth muscle cells

UBR4

:   Ubiquitin N-recognin domain-containing E3 ligase 4

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

We are thankful to Sumantra Chatterjee (NYU School of Medicine, USA) for his suggestions on the paper and an English native speaker at Faculty of Medicine, Public Health and Nursing, UGM, for checking our manuscript.

G conceived the study and drafted the manuscript, while EP, KI, and AM critically revised the manuscript for important intellectual content. ASK, EL, ARF, DNS, DA, and SMSK performed the total RNA extraction, qPCR, and collected the baseline data. G and ASK analyzed the data. All authors have approved the manuscript, and agreed to be accountable for all aspects of the study.

A grant was given by the Indonesia Ministry of Research, Technology and Higher Education (World Class Research No. 1979/UN1.DITLIT/DIT-LIT/LT/2019 to G.).

All data generated during this study are contained in the submission. The raw data are available from the corresponding author on reasonable request.

The Institutional Review Board of Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito Hospital approved this study (KE/FK/1105/EC/2018). The parents of HSCR patients and controls gave a signed informed consent before joining the study.

Not applicable.

The authors declare that they have no competing interests.
